首頁 › 急性雙表型白血病 › 華盛頓州 › Seattle
Seattle, WA 的 急性雙表型白血病 臨床試驗
15 項針對 急性雙表型白血病 的研究正在 Seattle（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
招募中1 期
- Fred Hutchinson Cancer Center, Seattle
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
招募中2 期
- Seattle Children's Hospital, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
招募中1 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
招募中
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
招募中3 期
- Seattle Children's Hospital, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Seattle Children's Hospital, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
招募中2 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
招募中2 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
招募中1/2 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
招募中1/2 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
招募中2 期歡迎健康志工
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
招募中1 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
招募中1/2 期歡迎健康志工
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
招募中1/2 期
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
招募中1 期
- Seattle Children's Hospital, Seattle
其他城市的 急性雙表型白血病 試驗
- Houston, TX11 項研究
- New York City, NY10 項研究
- Atlanta, GA9 項研究
- Durham, NC8 項研究
- Memphis, TN7 項研究
- Chicago, IL7 項研究
- Charlotte, NC6 項研究
- Aurora, CO6 項研究
- Baldwin Park, CA6 項研究
- Portland, OR6 項研究
- Los Angeles, CA6 項研究
- Philadelphia, PA6 項研究
Seattle 的其他研究
- 非小細胞肺癌53 項研究
- 癌症（所有類型）49 項研究
- 前列腺癌42 項研究
- 急性髓系白血病40 項研究
- 乳癌39 項研究
- 轉移性癌症39 項研究
- 大腸直腸癌34 項研究
- 肺癌33 項研究
- 卵巢癌30 項研究
- 多發性骨髓瘤22 項研究
- 骨髓增生異常症候群21 項研究
- 急性淋巴母細胞性白血病21 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。